

11/353307

FILE 'CAPLUS' ENTERED AT 23:48:30 ON 29 OCT 2006
L4 8 S L3

FILE 'CAOLD' ENTERED AT 23:49:58 ON 29 OCT 2006

=> s l3
L5 0 L3

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	0.44	209.83
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-6.00

FILE 'REGISTRY' ENTERED AT 23:50:11 ON 29 OCT 2006
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2006 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES: 27 OCT 2006 HIGHEST RN 911422-45-2
DICTIONARY FILE UPDATES: 27 OCT 2006 HIGHEST RN 911422-45-2

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 30, 2006

Please note that search-term pricing does apply when
conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document. For information
on property searching in REGISTRY, refer to:

<http://www.cas.org/ONLINE/UG/regprops.html>

=> save l3
ENTER NAME OR (END):ten502261/a
ANSWER SET L3 HAS BEEN SAVED AS 'TEN502261/A'

	SINCE FILE	TOTAL
	ENTRY	SESSION
COST IN U.S. DOLLARS		
FULL ESTIMATED COST	0.44	210.27
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)		
CA SUBSCRIBER PRICE	0.00	-6.00

SESSION WILL BE HELD FOR 120 MINUTES
STN INTERNATIONAL SESSION SUSPENDED AT 23:50:50 ON 29 OCT 2006

10/502261

8 L2

=> d l3 8 bib abs hitstr

L3 ANSWER 8 OF 8 CAPLUS COPYRIGHT 2006 ACS on STN
AN 2002:314909 CAPLUS
DN 136:325568
TI Preparation of 2-phenyl-4-piperazinylpiperidine-1-carboxylic acid
phenylalkylamides as tachykinin antagonists for treatment of CNS disorders
IN Alvaro, Giuseppe; Di Fabio, Romano; Maragni, Paolo; Tampieri, Marsia;
Tranquillini, Maria Elvira
PA Glaxo Group Limited, UK
SO PCT Int. Appl., 57 pp.
CODEN: PIXXD2
DT Patent
LA English
FAN.CNT 1

	PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
	-----	---	-----	-----	-----
PI	WO 2002032867	A1	20020425	WO 2001-GB4580	20011012
	W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
	RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
	CA 2425876	AA	20020425	CA 2001-2425876	20011012
	AU 2001095723	A5	20020429	AU 2001-95723	20011012
	EP 1326832	A1	20030716	EP 2001-976453	20011012
	EP 1326832	B1	20041006		
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				
	BR 2001014637	A	20030930	BR 2001-14637	20011012
	JP 2004511544	T2	20040415	JP 2002-536051	20011012
	AT 278669	E	20041015	AT 2001-976453	20011012
	PT 1326832	T	20050131	PT 2001-976453	20011012
	ES 2227287	T3	20050401	ES 2001-1976453	20011012
	EP 1524266	A1	20050420	EP 2004-77714	20011012
	R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, FI, CY, TR				
	NZ 525091	A	20050429	NZ 2001-525091	20011012
	NO 2003001561	A	20030614	NO 2003-1561	20030407
	ZA 2003002801	A	20040421	ZA 2003-2801	20030410
	US 2004014770	A1	20040122	US 2003-398264	20030729
	US 7119092	B2	20061010		
	HK 1058788	A1	20050527	HK 2004-100241	20040113
	US 2005137208	A1	20050623	US 2004-994605	20041122
	US 7060702	B2	20060613		
	AU 2005204234	A1	20050915	AU 2005-204234	20050824
	US 2006142302	A1	20060629	US 2006-358631	20060221
PRAI	GB 2000-25354	A	20001017		
	EP 2001-976453	A3	20011012		
	WO 2001-GB4580	W	20011012		
	US 2003-398264	A1	20030729		
	US 2004-994605	A1	20041122		
OS	MARPAT 136:325568				


GI

* STRUCTURE DIAGRAM TOO LARGE FOR DISPLAY - AVAILABLE VIA OFFLINE PRINT *

- AB Title compds. I [R = halo or alkyl; R1 = alkyl; R2 = H or alkyl; R3 = H or alkyl; R4 = CF₃; R5 = H, alkyl, or COR₆; R6 = (cyclo)alkyl or (di)alkylamino; m = 0-3; n = 1-3; and pharmaceutically acceptable salts and solvates thereof] were prepared as tachykinin antagonists. For example, reductive amination 2-(R)-(4-fluoro-2-methylphenyl)-4-oxopiperidine-1-carboxylic acid [1-(R)-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamide (preparation given) with 1-acetylpiperazine using sodium triacetoxyborohydride gave a mixture of diastereomers. 4(R)-II and 4-(S)-II were separated by flash chromatog. and the latter converted to its HCl salt. In a neurokinin 1 (NK1) receptor binding affinity assay, 4-(S)-II•HCl displace [3H]-substance P from recombinant human NK1 receptors expressed in Chinese Hamster Ovary cell membranes with pK_{iof} 9.36. In addition, oral administration of 4-(S)-II•HCl to gerbils inhibited foot tapping induced by an NK1 agonist with ED₅₀ of 0.05 mg/kg. I are useful for the treatment of CNS disorders, pain, sleep disorders, cognitive disorders, substance abuse, allergic disorders, emesis, gastrointestinal disorders, and depressive states (no data).
- IT 414910-17-1P 414910-18-2P 414910-31-9P
 414910-41-1P, 2-(R)-(4-Fluoro-2-methylphenyl)-4-(R)-[(4-tert-butoxycarbonyl)piperazin-1-yl]piperidine-1-carboxylic acid
 N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide
 414910-42-2P, 2-(R)-(4-Fluoro-2-methylphenyl)-4-(S)-[4-(tert-butoxycarbonyl)piperazin-1-yl]piperidine-1-carboxylic acid
 N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide
 RL: RCT (Reactant); SPN (Synthetic preparation); PREP (Preparation); RACT (Reactant or reagent)
 (intermediate; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
- RN 414910-17-1 CAPLUS
- CN 1-Piperazinecarboxylic acid, 4-[(2R,4R)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/502261



RN 414910-18-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2R,4S)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 414910-31-9 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/502261



RN 414910-41-1 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2R,4R)-1-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-42-2 CAPLUS

CN 1-Piperazinecarboxylic acid, 4-[(2R,4S)-1-[[[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-, 1,1-dimethylethyl ester (9CI) (CA INDEX NAME)

Absolute stereochemistry.



IT 414910-26-2P, 4-(R)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-27-3P, 4-(S)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-36-4P, 4-(R)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-(3,5-bis-trifluoromethylbenzyl)-N-methylamide 414910-37-5P, 4-(S)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-(3,5-bis-trifluoromethylbenzyl)-N-methylamide 414910-39-7P, 2-(R)-(4-Fluoro-2-methylphenyl)-4-(R,S)-(4-methyl-1-piperazinyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-43-3P, 2-(R)-(4-Fluoro-2-methylphenyl)-4-(S)-piperazin-1-ylpiperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-45-5P 414910-47-7P, 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-50-2P, 4-(S)-[4-(2-Methylpropanoyl)piperazin-1-yl]-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-53-5P 414910-55-7P 414910-56-8P 414910-58-0P, 4-(S)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluorophenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide


RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)

RN 414910-26-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/502261



RN 414910-27-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 414910-36-4 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R) - (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/502261



RN 414910-37-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 414910-39-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(4-methyl-1-piperazinyl)-, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/502261



RN 414910-43-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(1-piperazinyl)-, (2R,4S)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.




RN 414910-45-5 CAPLUS

CN 1-Piperidinecarboxamide, N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(4-methyl-1-piperazinyl)-, (2R)- (9CI)
(CA INDEX NAME)

Absolute stereochemistry.


10/502261



RN 414910-47-7 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 414910-50-2 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/502261



RN 414910-53-5 CAPLUS

CN 1-Piperazinecarboxamide, 4-[(2R,4S)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-N,N-dimethyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 414910-55-7 CAPLUS

CN 1-Piperazinecarboxamide, 4-[(2R,4S)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-N-methyl- (9CI) (CA INDEX NAME)

Absolute stereochemistry.


10/502261



RN 414910-56-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[2-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-4-(1-piperazinyl)-, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-58-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluorophenyl)-N-methyl-, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




- IT 414910-28-4P, 4-(R)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 414910-29-5P, 4-(S)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 414910-30-8P, 4-(S)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide methanesulfonate
 414910-32-0P 414910-33-1P, 4-(S)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide p-toluenesulfonate
 414910-34-2P, 4-(R)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-(3,5-bis-trifluoromethylbenzyl)-N-methylamide hydrochloride
 414910-35-3P, 4-(S)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-(3,5-bis-trifluoromethylbenzyl)-N-methylamide hydrochloride 414910-38-6P
 414910-40-0P, 2-(R)-(4-Fluoro-2-methylphenyl)-4-(S)-(piperazin-1-yl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide monohydrochloride
 414910-44-4P 414910-46-6P, 4-(R)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-48-8P, 4-(S)-(4-Cyclopropanoylpiperazin-1-yl)-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide hydrochloride
 414910-49-9P, 4-(R)-[4-(2-Methylpropanoyl)piperazin-1-yl]-2-(R)-(4-fluoro-2-methylphenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-51-3P
 414910-52-4P 414910-54-6P 414910-57-9P, 4-(R)-(4-Acetylpiperazin-1-yl)-2-(R)-(4-fluorophenyl)piperidine-1-carboxylic acid N-[1-(R)-(3,5-bis-trifluoromethylphenyl)ethyl]-N-methylamide 414910-59-1P
 RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
 (tachykinin antagonist; preparation of piperazinylpiperidinecarboxylic acid phenylalkylamides as tachykinin antagonists for treatment of CNS disorders)
 RN 414910-28-4 CAPLUS

10/502261

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 414910-29-5 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

RN 414910-30-8 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-

10/502261


bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-,
(2R,4S)-, monomethanesulfonate (9CI) (CA INDEX NAME)

CM 1

CRN 414910-27-3

CMF C30 H35 F7 N4 O2


Absolute stereochemistry.



CM 2

CRN 75-75-2

CMF C H4 O3 S



RN 414910-32-0 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-,
(2R,4S)-, sulfate (2:1) (9CI) (CA INDEX NAME)


CM 1

CRN 414910-27-3

CMF C30 H35 F7 N4 O2

Absolute stereochemistry.


10/502261



CM 2

CRN 7664-93-9

CMF H2 O4 S



RN 414910-33-1 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4S)-, mono(4-methylbenzenesulfonate) (9CI) (CA INDEX NAME)


CM 1

CRN 414910-27-3

CMF C30 H35 F7 N4 O2

Absolute stereochemistry.


10/502261



CM 2

CRN 104-15-4


CMF C7 H8 O3 S



RN 414910-34-2 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

10/502261

RN 414910-35-3 CAPLUS

CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-38-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(4-methyl-1-piperazinyl)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 414910-40-0 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(1-piperazinyl)-, monohydrochloride, (2R)- (9CI) (CA INDEX NAME)

10/502261

monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 414910-44-4 CAPLUS

CN 1-Piperidinecarboxamide, N-[[[3,5-bis(trifluoromethyl)phenyl]methyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-(4-methyl-1-piperazinyl)-, dihydrochloride, (2R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


●2 HCl

10/502261

RN 414910-46-6 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, (2R,4R)- (9CI) (CA INDEX NAME)


Absolute stereochemistry.



RN 414910-48-8 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-4-[4-(cyclopropylcarbonyl)-1-piperazinyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




● HCl

RN 414910-49-9 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-, (2R,4R)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.




RN 414910-51-3 CAPLUS

CN 1-Piperidinecarboxamide, N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluoro-2-methylphenyl)-N-methyl-4-[4-(2-methyl-1-oxopropyl)-1-piperazinyl]-, monohydrochloride, (2R,4S)- (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A


● HCl

RN 414910-52-4 CAPLUS

CN 1-Piperazinecarboxamide, 4-[(2R,4S)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-N,N-dimethyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A




PAGE 2-A

● HCl

RN 414910-54-6 CAPLUS
 CN 1-Piperazinecarboxamide, 4-[(2R,4S)-1-[[[3,5-bis(trifluoromethyl)phenyl]methyl]methylamino]carbonyl]-2-(4-fluoro-2-methylphenyl)-4-piperidinyl]-N-methyl-, monohydrochloride (9CI) (CA INDEX NAME)

Absolute stereochemistry.


PAGE 1-A



● HCl


RN 414910-57-9 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluorophenyl)-N-methyl-, (2R,4R)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



RN 414910-59-1 CAPLUS
CN 1-Piperidinecarboxamide, 4-(4-acetyl-1-piperazinyl)-N-[(1R)-1-[3,5-bis(trifluoromethyl)phenyl]ethyl]-2-(4-fluorophenyl)-N-methyl-, monohydrochloride, (2R,4S)-(9CI) (CA INDEX NAME)

Absolute stereochemistry.



● HCl

10/502261

RE.CNT 2 THERE ARE 2 CITED REFERENCES AVAILABLE FOR THIS RECORD
ALL CITATIONS AVAILABLE IN THE RE FORMAT